Allergan has signed a deal potentially worth $1.5 billion with Molecular Partners to develop new drugs for certain eye diseases. …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

